Enterobiotix - About the company
Enterobiotix is a series B company based in Edinburgh (United Kingdom), founded in 2017 by James McIlroy. It operates as a Developer of microbiome-based therapeutics for multiple disease targets. Enterobiotix has raised $98M in funding from investors like Kineticos, Equity Gap and The Scottish National Investment Bank. The company has 2598 active competitors, including 889 funded and 647 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.
Company Details
Developer of microbiome-based therapeutics for multiple disease targets. The company is engaged in developing an integrated anaerobic system which comprises of a closed system collection and processing benchtop system that will allow therapies to be produced outside of cleanrooms and in anaerobic environments. It aims to offer microbiome therapy to patients suffering from Inflammatory Bowel Disease and other diseases related to the gut.
- Website
- www.enterobiotix.com/
- Social
Key Metrics
Founded Year
2017
Location
Edinburgh, United Kingdom
Stage
Series B
Total Funding
$98M in 10 rounds
Latest Funding Round
Ranked
188th among 2598 active competitors
Annual Revenue
£0 - £1M as on Dec 31, 2025
Employee Count
43 as on Sep 30, 2026
Similar Companies
Legal entities associated with Enterobiotix
Enterobiotix is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
ENTEROBIOTIX LIMITED CIN: SC559230 , United Kingdom, Active | Mar 01, 2017 | £0 - £1M (As on Dec 31, 2025) | 8 (As on Mar 31, 2019) |
Sign up to download Enterobiotix's company profile
Enterobiotix's funding and investors
Enterobiotix has raised a total funding of $98M over 10 rounds. Its first funding round was on Jun 21, 2017. Its latest funding round was a Series B round on Apr 29, 2026 for $*****. 2 investors participated in its latest round. Enterobiotix has 15 institutional investors.
Here is the list of recent funding rounds of Enterobiotix:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 29, 2026 | 5100278 | Series B | 4578811 | 8485676 | 9010050 | 1732425 |
Mar 30, 2026 | 5609826 | Series B | 1140120 | 6730708 | 8419840 | 4171995 |
Jul 11, 2025 | 7646510 | Series B | 8711185 | 2580680 | 2723868 | 2276666 |
Access funding benchmarks and valuations. Sign up today!View details of Enterobiotix's funding rounds and investors
Enterobiotix's founders and board of directors
Founder? Claim ProfileThe founders of Enterobiotix is James McIlroy. James McIlroy is the CEO of Enterobiotix.
Here are the details of Enterobiotix's key team members:
- James McIlroy: Founder & CEO of Enterobiotix. Contact Info: 1 email address
View details of Enterobiotix's Founder profiles and Board Members
Enterobiotix's employee count trend
Enterobiotix has 43 employees as of Sep 26. Here is Enterobiotix's employee count trend over the years:
Uncover Enterobiotix's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Enterobiotix's Competitors and alternates
Top competitors of Enterobiotix include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Enterobiotix, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
3rd | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
4th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
5th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
6th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
7th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
8th | _1545299782322.png?devicePixelRatio=2&height=30&width=30){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
9th |  Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 71/100 | |
10th |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 71/100 | |
188th | Enterobiotix 2017, Edinburgh (United Kingdom), Series B | Developer of microbiome-based therapeutics for multiple disease targets | $98M | 49/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Enterobiotix's competitors? Click here to see the top ones
Enterobiotix's Investments and acquisitions
Enterobiotix has made no investments or acquisitions yet.
Reports related to Enterobiotix
Here is the latest report on Enterobiotix's sector:
News related to Enterobiotix
Filter this listMedia has covered Enterobiotix for a total of 3 events in the last 1 year, 1 of them has been about company updates.
•
EnteroBiotix Secures £19m to Fund Phase 2b Clinical Trial for Irritable Bowel SyndromeGlobeNewswire•Apr 29, 2026•The Scottish National Investment Bank, Enterobiotix
•
EnteroBiotix Completes Enrollment in Phase IIa MAST Trialclinicaltrialsarena.com•Mar 11, 2026•Enterobiotix
•
EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025GlobeNewswire•Apr 28, 2025•Enterobiotix
•
EnteroBiotix's IBS drug EBX-102-02 shows positive early trial results.GlobeNewswire•Mar 18, 2025•Enterobiotix
•
EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver CirrhosisGlobeNewswire•Nov 11, 2024•Enterobiotix
•
IBS specialist EnteroBiotix closes £27m funding roundHerald Scotland•Apr 05, 2024•Enterobiotix, The Scottish National Investment Bank, Kineticos, Scottish Enterprise
•
•
•
EnteroBiotix partners with Imperial College London to develop microbiome therapeuticsPR Newswire•Nov 09, 2022•Enterobiotix, Imperial
•
EnteroBiotix receives MHRA MIA (IMP) licensure of state-of-the-art GMP manufacturing facility for producing microbiome therapeuticsPR Newswire•Oct 11, 2022•Enterobiotix
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Enterobiotix
Explore our recently published companies
- Cocoons - San Luis Obispo based, 2001 founded, Unfunded company
- TechPulley - Taiwan based, 1996 founded, Unfunded company
- Health Works - Bryan based, Unfunded company
- SRITECH - Nagpur based, 1995 founded, Unfunded company
- Witte Werbetechnik - Amelinghausen based, Unfunded company
- Nexarcane Forensics & Technology - Bengaluru based, 2024 founded, Unfunded company
